Meghna Dua, MD, Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, presented data from her team’s findings regarding hydroxyurea dosing in very young children with sickle cell disease (SCA) during the American Society of Hematology (ASH) Annual Meeting and Exposition. With little published research on infants’ tolerance to hydroxyurea dose escalation, Dua and …
A pair of pyruvate kinase (PKA) activators have been linked to increased oxygen affinity and reduced propensity for red blood cell sickling in patients with sickle cell disease in vitro, according to new findings. In data presented at the 2022 Annual Meeting of the American Society of Hematology (ASH) in New Orleans this week, a …
Pyruvate kinase activators may benefit vaso-occlusive crisis in sickle cell disease Read More »
People with sickle cell disease (SCD) present to the emergency department (ED) and are often hospitalized, most often for episodes of vaso-occlusive pain (VOE). These episodes, also called “pain crises” because of the intense pain experienced by patients, cause acute arginine (Arg) deficiency. Arg supplementation has shown positive effects on blood pressure, cardiopulmonary function and …
Arganine therapy shows positive impacts on sickle cell disease in ASH 2022 data Read More »
Researchers from the Alfred E. Mann Department of Biomedical Engineering at the University of Southern California have developed a “heart attack on a chip,” a device that could one day serve as a test bed for developing new heart drugs and even personalized drugs. “Our device replicates some key features of a heart attack in …
In 2015, a 78-year-old Florida woman suddenly lost sight in both eyes after receiving stem cell treatment for macular degeneration. The therapy she underwent at a clinic involved a unique type of eye injection containing stem cells made from body fat. When her ophthalmologist examined her later, he saw chunks of blood floating in her …
To prevent animal testing and create even more accurate ways to test therapeutics, the pharmaceutical industry is increasingly turning to human immune cells. However, the availability of cells like these has been limited to date. Now, Fraunhofer researchers have succeeded in taking the production of personalized immune cells from the laboratory to the industrial level. …
Increasing production of custom immune cells for drug development and testing Read More »
Changes in a single gene open the door for harmful gut bacteria to trigger the inflammation that leads to Crohn’s disease, according to a new study led by Weill Cornell Medicine and NewYork-Presbyterian researchers. These findings could one day help doctors better select targeted treatments for patients with this immune disorder. This particular host gene, …
Harmful gut bacteria co-opt genetic susceptibility to trigger Crohn’s disease Read More »
Published Medicine, Inc. CAMBRIDGE, Mass., Dec. 01 10, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the RUBY Phase 1/2 trial of EDIT-301, being developed for …
Laertis Ikonomou In early September 2022, a court ruling in California caused a minor shock to the cell and gene therapy scene. A landmark and potentially controversial decision by the Honorable Judge Jesus G. Bernal of the Central District of California has ruled that stem cell treatments offered by the Cell Surgical Network company of …
1. In this phase 3 non-randomized controlled trial, among 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving dendritic cell vaccination (DCVax-L) had a median overall survival of 19.3 months versus 16.5 months in outpatient control patients treated with standard of care. 2. Patients with recurrent glioblastoma (rGBM) had a median overall survival of 13.2 …
